Early-stage growth Target rehabilitation centers and small clinics focusing on stroke and spinal cord injury recovery, highlighting Rehabtronics' ReJoyce, ReTouch, and ReGrasp as compact, specialized neurorehabilitation solutions with potential for pilot programs.

Strategic partnerships Leverage Genome BC funding history to pursue collaborations with research institutions and provincial health networks for free quality improvement trials of Prelivia, creating validation case studies that can drive payer and hospital adoption.

US market entry Capitalize on the May 2022 US launch of ReGrasp Bionic Glove by targeting US clinics, stroke centers, and durable medical equipment distributors with ROI-focused materials emphasizing accelerated hand rehabilitation outcomes.

Cost-conscious sales Position as a low-volume, high-impact medical device company with a lean team by offering bundled purchasing options, implementation support, and remote monitoring to small clinics seeking affordable, scalable neurorehabilitation tech.

Funding-led traction Highlight recent oversubscribed funding and ongoing financing as proofs of momentum to engage venture-backed startups, hospital networks exploring innovation, and grant programs seeking scalable neurorehabilitation solutions with measurable outcomes.